Use of High-Resolution Volumetric MR Spectroscopic Imaging in Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor

• Type of Material: Article
• Authors: Hyunsuk Shim, Emory University; Li Wei, Emory University; Andrew H Miller, Emory University; Jeffrey James Olson, Emory University; Chad A Holder, Emory University; Ying Guo, Emory University; Xiaoping P Hu, Emory University
• Language: English
• Date: 2014-08-01
• Publisher: American Roentgen Ray Society (ARRS)
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © American Roentgen Ray Society.
• Final Published Version (URL): http://dx.doi.org/10.2214/AJR.14.12518
• Title of Journal or Parent Work: American Journal of Roentgenology
• ISSN: 0361-803X
• Volume: 203
• Issue: 2
• Start Page: W158
• End Page: W165
• Grant/Funding Information: This work was supported by National Institutes of Health grants NIH/NCI R21 CA141836 and NIH/NCI U01 CA172027.
• Keywords: POSITRON EMISSION TOMOGRAPHY; glioblastoma histone deacetylase (HDAC); PSEUDOPROGRESSION; TRUE PROGRESSION; MULTIFORME; MR spectroscopic imaging; RADIOTHERAPY; vorinostat; Life Sciences & Biomedicine; ADJUVANT TEMOZOLOMIDE; GLIOMA; CONCOMITANT; Radiology, Nuclear Medicine & Medical Imaging; PATTERNS; epigenetic modification; HUMAN BRAIN-TUMORS; Science & Technology
• Research Categories: Health Sciences, Oncology; Health Sciences, Radiology

Abstract

OBJECTIVE. Improved predictive imaging would enable personalization and adjustment of treatment, which are critical for patients with glioblastomain whom therapy is likely to fail. This article describes the use of MR spectroscopic imaging (MRSI) to predict early clinical and behavioral response to a therapy and an effort to develop high-resolution, volumetric MRSI to improve its clinical application. CONCLUSION. MRSI may enable quantitative analysis of brain tumor response, offering a precise tool for monitoring of patients in clinical trials.